Epacadostat
Epacadostat is an investigational drug that acts as an inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). It is being studied for its potential use in cancer immunotherapy.
Mechanism of Action[edit]
Epacadostat works by inhibiting the activity of IDO1, an enzyme that is involved in the metabolism of tryptophan into kynurenine. IDO1 is often overexpressed in various types of tumors, leading to an immunosuppressive environment that allows cancer cells to evade the immune system. By blocking IDO1, epacadostat aims to restore the immune system's ability to recognize and attack cancer cells.
Clinical Development[edit]
Epacadostat has been evaluated in several clinical trials for its efficacy and safety in treating different types of cancer. It has been studied both as a monotherapy and in combination with other immunotherapeutic agents, such as checkpoint inhibitors like pembrolizumab and nivolumab.
Key Clinical Trials[edit]
- ECHO-301/KEYNOTE-252: This was a Phase 3 clinical trial that evaluated the combination of epacadostat and pembrolizumab in patients with advanced melanoma. The trial did not meet its primary endpoint of progression-free survival.
- ECHO-202/KEYNOTE-037: This Phase 1/2 trial investigated the combination of epacadostat and pembrolizumab in patients with various advanced solid tumors, including non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma.
Side Effects[edit]
The most common side effects observed in clinical trials of epacadostat include fatigue, nausea, rash, and diarrhea. Serious adverse events have also been reported, including immune-related adverse events.
Future Directions[edit]
Despite the setback in the ECHO-301/KEYNOTE-252 trial, research continues to explore the potential of IDO1 inhibitors like epacadostat in combination with other therapeutic agents. Ongoing studies are investigating different dosing regimens, combinations with other immunotherapies, and the identification of biomarkers that may predict response to treatment.
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help Wikipedia by adding missing information. |
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
